SWK Holdings focuses on pharmaceutical development, manufacturing and intellectual property licensing business. Co.'s operations comprise two reportable segments: Finance Receivables, which provides customized financing solutions to a range of life science companies, institutions and inventors, and focuses on commercial-stage products and related intellectual property through royalty purchases and financings, as well as through commercialized products; and Pharmaceutical Development, in which through its subsidiary, Enteris BioPharma, Inc., provides formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence® platform. We show 19 historical shares outstanding datapoints in our coverage of SWKH's shares outstanding history.
Understanding the changing numbers of SWKH shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like SWKH versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching SWKH by allowing them to research SWKH shares outstanding history
as well as any other stock in our coverage universe. |
Free SWKH Email Alerts:
Video: Shares Outstanding Importance
